Beneficial effect of rosuvastatin on cardiac dysfunction is associated with alterations in calcium-regulatory proteins

European Journal of Heart Failure

Volumn 11, Issue 1, 2009, Pages 6-13

  Yang, Ying ^a   Mou, Yun ^a   Hu, Shen Jiang ^a,b   Fu, Michael ^c  

^a ZHEJIANG UNIVERSITY   (China)

^b Immunology Division   (China)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cardiac dysfunction; Interleukin; Myocardial infarction; Phospholamban; Rosuvastatin; Sarcoplasmic reticulum Ca2+ ATPase

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 10; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLAMBAN; PHOSPHOPHOSPHOLAMBAN; PHOSPHOPROTEIN; ROSUVASTATIN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2A; SERINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ATP2A2 PROTEIN, MOUSE; CALCIUM BINDING PROTEIN; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; HEART HEMODYNAMICS; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HEART WEIGHT; LIPID BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ANIMAL; BLOOD; DISEASE MODEL; HEART; METABOLISM; ORGAN SIZE; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; CALCIUM-BINDING PROTEINS; DISEASE MODELS, ANIMAL; FLUOROBENZENES; HEART; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERLEUKIN-10; INTERLEUKIN-6; MALE; ORGAN SIZE; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SULFONAMIDES; VENTRICULAR REMODELING;

EID: 62449222305     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfn002     Document Type: Article

References (28)

1. Vangheluwe P, Raeymaekers L, Dode L, Wuytack F. Modulating sarco(endo) plasmic reticulum Ca2+ ATPase 2 (SERCA2) activity: cell biological implications. Cell Calcium 2005;38:291 -302.
2. Periasamy M, Huke S. SERCA pump level is a critical determinant of Ca(2+) homeostasis and cardiac contractility. J Mol Cell Cardiol 2001 ;33: 1053-1063.
3. Piacentino V III, Weber CR, Chen X, Weisser-Thomas J, Margulies KB, Bers DM, Houser SR. Cellular basis of abnormal calcium transients of failing human ventricular myocytes. Circ Res 2003;92:651-658.
4. Hasenfuss G. Alterations of calcium-regulatory proteins in heart failure. Cardiovasc Res 1998;37:279-289.
5. Tavazzi L, Tognoni G, Franzosi MG, Latini R, Maggioni AP, Marchioli R, Nicolosi GL, Porcu M. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail 2004;6:635-641.
6. Kjekshus J, Dunselman P, Blideskog M, Eskilson C, Hjalmarson A, McMurray JV, Waagstein F, Wedel H, Wessman P, Wikstrand J. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail 2005;7: 1059-1069.
7. Ohara Y, Hiasa Y, Hosokawa S, Miyazaki S, Ogura R, Miyajima H, Yuba K, Suzuki N, Takahashi T, Kishi K, Ohtani R. Impact of hydroxymethylglutaryl coen-zyme A reductase inhibition on left ventricular remodeling in patients with acute anterior myocardial infarction after primary coronary angioplasty. Int Heart J 2005; 46:987-995.
8. Zheng X, Hu SJ. Effects of simvastatin on cardiac performance and expression of sarcoplasmic reticular calcium regulatory proteins in rat heart. Acta Pharmacol Sin 2005;26:696-704.
9. Jones SP, Gibson MF, Rimmer DM III, Gibson TM, Sharp BR, Lefer DJ. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol 2002;40:1172-1178.
10. Mozaffarian D, Minami E, Letterer RA, Lawler RL, McDonald GB, Levy WC. The effects of atorvastatin (10 mg) on systemic inflammation in heart failure. Am J Cardiol 2005;96:1699-1704.
11. Goldman S, Raya TE. Rat infarct model of myocardial infarction and heart failure. J Card Fail 1995;1:169-177.
12. Kodavanti PR, Cameron JA, Yallapragada PR, Desaiah D. Effect of chlordecone (Kepone) on calcium transport mechanisms in rat heart sarcoplasmic reticulum. Pharmacol Toxicol 1990;67:227-234.
13. Jones LR. Mg2+ and ATP effects on K+ activation of the Ca2+-transport ATPase of cardiac sarcoplasmic reticulum. Biochim Biophys Acta 1979;557: 230-242.
14. van der Harst P, Voors AA, van Gilst WH, Bohm M, van Veldhuisen DJ. Statins in the treatment of chronic heart failure: a systematic review. PLoS Med 2006;3: e333.
15. Sironi L, Gianazza E, Gelosa P, Guerrini U, Nobili E, Gianella A, Cremonesi B, Paoletti R, Tremoli E. Rosuvastatin, but not simvastatin, provides end-organ protection in stroke-prone rats by antiinflammatory effects. Arterioscler Thromb Vasc Biol 2005;25:598-603.
16. Nicolosi GL. Cardiac remodeling and failure after myocardial infarction. J Cardiovasc Risk 1994;1:310-313.
17. Endo A, Tsujita Y, Kuroda M, Tanzawa K. Effects of ML-236B on cholesterol metabolism in mice and rats: lack of hypocholesterolemic activity in normal animals. Biochim Biophys Acta 1979;575:266-276.
18. Tousoulis D, Charakida M, Stefanadi E, Siasos G, Latsios G, Stefanadis C. Statins in heart failure. Beyond the lipid lowering effect. Int J Cardiol 2007;115: 144-150.
19. Sun YL, Hu SJ, Wang LH, Hu Y, Zhou JY. Effect of beta-blockers on cardiac function and calcium handling protein in postinfarction heart failure rats. Chest 2005; 128:1812-1821.
20. Perez-Guerrero C, Alvarez de Sotomayor M, Herrera MD, Marhuenda E. Endo-thelium modulates contractile response to simvastatin in rat aorta. Z Naturforsch [C] 2000;55:121-124.
21. Sirvent P, Mercier J, Vassort G, Lacampagne A. Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle. Biochem Biophys Res Commun 2005;329:1067-1075.
22. Hill BJ, Dixon JL, Sturek M. Effect of atorvastatin on intracellular calcium uptake in coronary smooth muscle cells from diabetic pigs fed an atherogenic diet. Atherosclerosis 2001;159:117-124.
23. Candia AM, Villacorta Junior H, Mesquita ET. Immune-inflammatory activation in heart failure. Arq Bras Cardiol 2007;89:201-208.
24. Bolger AP, Sharma R, von Haehling S, Doehner W, Oliver B, Rauchhaus M, Coats AJ, Adcock IM, Anker SD. Effect of interleukin-10 on the production of tumor necrosis factor-alpha by peripheral blood mononuclear cells from patients with chronic heart failure. AmJ Cardiol 2002;90:384-389.
25. Tanaka T, Kanda T, Takahashi T, Saegusa S, Moriya J, Kurabayashi M. Interleukin-6-induced reciprocal expression of SERCA and natriuretic peptides mRNA in cultured rat ventricular myocytes. J Int Med Res 2004;32:57-61.
26. Villegas S, Villarreal FJ, Dillmann WH. Leukemia Inhibitory Factor and Interleukin-6 downregulate sarcoplasmic reticulum Ca2p ATPase (SERCA2) in cardiac myocytes. Basic Res Cardiol 2000;95:47-54.
27. Yu XW, Chen Q, Kennedy RH, Liu SJ. Inhibition of sarcoplasmic reticular function by chronic interleukin-6 exposure via iNOS in adult ventricular myocytes. J Physiol 2005;566:327-340.
28. Takemoto M, LiaoJK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;21:1712-1719.